{
  "id": 16612781,
  "title": "Adding abiraterone to ADT and docetaxel improves survival in metastatic prostate cancer",
  "url": "https://urgent.news/2026/10/26/adding-abiraterone-to-adt-and-docetaxel-improves-survival-in",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-26T13:40:01.000Z",
  "source": {
    "name": "Medical Xpress",
    "slug": "medical-xpress",
    "url": "https://medicalxpress.com/news/2026-10-adding-abiraterone-adt-docetaxel-survival.html"
  },
  "original_language": "en",
  "account": null,
  "summary": "Adding abiraterone to standard treatment provides a lasting survival benefit for men whose prostate cancer has already spread at diagnosis, reinforcing the value of early treatment intensification. The findings come from almost eight years of follow-up in the academically led phase 3 PEACE-1 trial presented at the ESMO Congress 2026.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}